Koch U - Search Results

1

Residual γH2AX foci predict local tumour control after radiotherapy.

Koch U, Höhne K, von Neubeck C, Thames HD, Yaromina A, Dahm-Daphi J, Baumann M, Krause M. Koch U, et al. Radiother Oncol. 2013 Sep;108(3):434-9. doi: 10.1016/j.radonc.2013.06.022. Epub 2013 Jul 25. Radiother Oncol. 2013. PMID: 23891089

2

Cancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective.

Koch U, Krause M, Baumann M. Koch U, et al. Semin Cancer Biol. 2010 Apr;20(2):116-24. doi: 10.1016/j.semcancer.2010.02.003. Epub 2010 Feb 26. Semin Cancer Biol. 2010. PMID: 20219680 Review.

3

Cancer stem cells: targets and potential biomarkers for radiotherapy.

Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. Krause M, et al. Among authors: koch u. Clin Cancer Res. 2011 Dec 1;17(23):7224-9. doi: 10.1158/1078-0432.CCR-10-2639. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976536

4

Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer.

Singer A, Deuse Y, Koch U, Hölscher T, Pfitzmann D, Jakob C, Hehlgans S, Baretton GB, Rentsch A, Baumann M, Muders MH, Krause M. Singer A, et al. Among authors: koch u. Strahlenther Onkol. 2012 Dec;188(12):1125-32. doi: 10.1007/s00066-012-0228-7. Epub 2012 Nov 7. Strahlenther Onkol. 2012. PMID: 23128896

5

PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha.

Eke I, Koch U, Hehlgans S, Sandfort V, Stanchi F, Zips D, Baumann M, Shevchenko A, Pilarsky C, Haase M, Baretton GB, Calleja V, Larijani B, Fässler R, Cordes N. Eke I, et al. Among authors: koch u. J Clin Invest. 2010 Jul;120(7):2516-27. doi: 10.1172/JCI41078. Epub 2010 Jun 7. J Clin Invest. 2010. PMID: 20530873 Free PMC article.

6

Cell adhesion-mediated radioresistance revisited.

Sandfort V, Koch U, Cordes N. Sandfort V, et al. Among authors: koch u. Int J Radiat Biol. 2007 Nov-Dec;83(11-12):727-32. doi: 10.1080/09553000701694335. Int J Radiat Biol. 2007. PMID: 17952769 Review.

7

[Therapy of advanced hypopharyngeal carcinoma].

Rauchfuss A, Koch U. Rauchfuss A, et al. Among authors: koch u. Strahlenther Onkol. 1987 Aug;163(8):525-8. Strahlenther Onkol. 1987. PMID: 3629467 German.

8

Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.

Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, Fahlbusch R. Schrell UM, et al. Among authors: koch uh. J Neurosurg. 1997 May;86(5):845-52. doi: 10.3171/jns.1997.86.5.0845. J Neurosurg. 1997. PMID: 9126901

9

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R. Schrell UM, et al. Among authors: koch uh. J Neurosurg. 1997 May;86(5):840-4. doi: 10.3171/jns.1997.86.5.0840. J Neurosurg. 1997. PMID: 9126900 Clinical Trial.

10

Hydroxyurea for treatment of unresectable meningiomas.

Schrell UM, Rittig MG, Koch U, Marschalek R, Anders M. Schrell UM, et al. Among authors: koch u. Lancet. 1996 Sep 28;348(9031):888-9. doi: 10.1016/S0140-6736(05)64757-5. Lancet. 1996. PMID: 8826822 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

632 results

Search Page